ILLUMINATE

• Research type

  Research Study

• Full title

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension

• IRAS ID

  1013073

• Contact name

  Danis Subramanian

• Contact email

  danise.subramaniam@regeneron.com

• Sponsor organisation

  Regeneron Pharmaceuticals

• Clinicaltrials.gov Identifier

  NCT07318597

• Research summary

  This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines.
  
  The study is looking at several other research questions, including:
  • What side effects may happen from taking REGN13335
  • How much REGN13335 is in the blood at different times
  • Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)
  
  This is a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. The study will include: a Double-Blind Treatment Period (DBTP) and an Open-Label Extension (OLE) period for participants who choose to continue treatment. Approximately 99 participants from 12 countries will take part in the study.
  
  Regeneron Pharmaceuticals, Inc is the Sponsor

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  25/LO/0916

• Date of REC Opinion

  13 Feb 2026

• REC opinion

  Further Information Favourable Opinion